Synergistic therapeutic effect of parecoxib and ilomastat combination in osteoarthritis via inhibition of IL-17/PI3K/AKT/NF-κB activity
Molecular Immunology · 2025
DOI: 10.1016/j.molimm.2025.02.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Immunology, 2025. Verfasst von Xiaofei Feng und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China. Hauptthemen laut MEDLINE: Osteoarthritis, Isoxazoles, Interleukin-17. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Lanzhou University First Affiliated Hospital.
Abstract (Originalsprache)
BACKGROUND: Osteoarthritis is a degenerative disease, and current drug treatment is to give nonsteroidal anti-inflammatory drugs to relieve symptoms. The anti-inflammatory ability of parecoxib and ilomastat has been confirmed, but the synergistic effect of combined administration in osteoarthritis has not been clear. METHODS: Mouse primary chondrocytes stimulated with IL-1β were cultured. The expression levels of inflammatory cytokines and matrix metalloproteinases were investigated by western blotting, quantitative real-time polymerase chain reaction and ELISA. The effects of parecoxib and ilomastat on chondrocyte apoptosis were evaluated by flow cytometry. In addition, the rat model of osteoarthritis was established by meniscal instability, and the morphological changes of cartilage and the expression levels of related molecules were monitored using Safranin O-Fast green and immunohistochemical staining after intra-articular injection of parecoxib, ilomastat, and the combination of the two. RESULTS: In vitro experiments showed that the combined administration of parecoxib and ilomastat more effectively inhibited the expression of proinflammatory factors and matrix metalloproteinases compared with single drug administration. The combined drug treatment could more effectively inhibit IL-1β-induced chondrocyte apoptosis. The combined drug treatment alleviated the progression of osteoarthritis by inhibiting the IL-17/PI3K/AKT/NF-κB pathway. In addition, in vivo experiments showed that the combined administration could improve the further deterioration of the osteoarthritis rat model. CONCLUSIONS: The combined administration of parecoxib and ilomastat to inhibit IL-17/PI3K/AKT/NF-κB transduction is beneficial to reduce the infiltration of inflammatory factors and matrix metalloproteinases in osteoarthritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China.
- Clinical Laboratory Center, Gansu Provincial Maternity and Child-Care Hospital, Lanzhou 730000, China.
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Research Unit of Peptide Science, Chinese Academy of Medical Sciences, 2019RU066, Institute of Biochemistry and Molecular Biology, School of Basic Med…
- The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China; The First Hospital of Lanzhou University, Lanzhou 730000, China. Electronic address: ldyywjw@163.com.
Förderung
- Lanzhou University First Affiliated Hospital
Zitieren
APA
Feng, X., Ma, Y., Zhao, Y., Zhao, Z., Song, Z., Lin, L., & Wang, W. (2025). Synergistic therapeutic effect of parecoxib and ilomastat combination in osteoarthritis via inhibition of IL-17/PI3K/AKT/NF-κB activity. Molecular Immunology. https://doi.org/10.1016/j.molimm.2025.02.005
Vancouver
Feng X, Ma Y, Zhao Y, Zhao Z, Song Z, Lin L, et al. Synergistic therapeutic effect of parecoxib and ilomastat combination in osteoarthritis via inhibition of IL-17/PI3K/AKT/NF-κB activity. Molecular Immunology. 2025. doi:10.1016/j.molimm.2025.02.005
BibTeX
@article{Feng2025,
author = {Feng, Xiaofei and Ma, Yao and Zhao, Yuhao and Zhao, Zhenrui and Song, Zhengdong and Lin, Li and Wang, Wenji},
title = {Synergistic therapeutic effect of parecoxib and ilomastat combination in osteoarthritis via inhibition of IL-17/PI3K/AKT/NF-κB activity},
journal = {Molecular Immunology},
year = {2025},
doi = {10.1016/j.molimm.2025.02.005}
}
EUVIMED